Efficacy and safety of praziquantel plus artemisinin-based combinations versus praziquantel in the treatment of Kenyan children with Schistosoma mansoni infection: open-label, randomized, head-to-head, non-inferiority trial
Wirksamkeit und Sicherheit von Praziquantel plus artemisininbasierten Kombinationen versus Praziquantel zur Behandlung kenianischer Kinder mit Schistosoma-mansoni-Infektion: offene, randomisierte, direkt vergleichende Nichtunterlegenheitsstudie
Antimicrobial Agents and Chemotherapy · 13.02.2025 · 69 (2)
DOI: 10.1128/aac.00739-24 ↗Auf einen Blick
Bei kenianischen Kindern mit Schistosoma mansoni war Praziquantel plus Artesunat-Mefloquin oder Praziquantel plus Dihydroartemisinin-Piperaquin nicht unterlegen gegenüber Praziquantel allein. Für die anderen Kombinationen galt das nicht.
Fragestellung
Ist Praziquantel plus eine artemisininbasierte Kombination Praziquantel allein bei Kindern mit Schistosoma-mansoni-Infektion hinsichtlich Heilungsrate und Nebenwirkungen nicht unterlegen?
Methode
Randomisierte, offene, fünfarmige Nichtunterlegenheitsstudie; Kinder 9–15 Jahre in Kenia; Vergleich von Praziquantel allein mit vier Kombinationen; Beurteilung nach 6 Wochen per Protokoll.
Ergebnisse
Heilungsraten: 82,5 % mit Praziquantel allein, 81,7 % mit As+SP, 76,2 % mit As+AQ, 88,7 % mit As+MQ, 85,7 % mit DHAP. Nichtunterlegenheit für As+MQ (Differenz 6,2; 95 %-KI −3,3 bis 15,6) und DHAP (3,2; −6,7 bis 13,1).
Schlussfolgerung der Autor:innen
Praziquantel plus Artesunat-Mefloquin oder Praziquantel plus Dihydroartemisinin-Piperaquin könnten Alternativen zu Praziquantel sein; weitere multizentrische Studien sind nötig.
Kernaussagen
- 82,5 % Heilung mit Praziquantel allein
- Nichtunterlegen: As+MQ und DHAP
- Unerwünschte Ereignisse bei 26 %; keine schweren Ereignisse
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Äquivalenzstudie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 13.02.2025. Verfasst von Charles O Obonyo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya. Hauptthemen laut MEDLINE: Anthelmintics, Artemisinins, Praziquantel, Schistosoma mansoni. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kenya Medical Research Institute (KEMRI).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Praziquantel alone is insufficient for the control of schistosomiasis due to poor efficacy against juvenile worms and increasing concerns about the risk of drug resistance. We compared the efficacy and safety of praziquantel combined with four different artemisinin-based combinations to praziquantel alone in treating Schistosoma mansoni infection in Kenyan children. In this randomized, open-label, five-arm, head-to-head, non-inferiority trial, children (aged 9–15 years) with S. mansoni infection according to duplicate Kato Katz thick smears from a stool sample in the Mwea irrigation scheme of central Kenya, were enrolled. Participants were randomly assigned (1:1:1:1:1) via a computer-generated block randomization procedure to receive a single oral dose of praziquantel (PZQ) (40 mg/kg/day) alone or in combination with a 3-day course (4 mg/kg of artesunate) of artesunate plus sulfalene-pyrimethamine (As + SP), artesunate plus amodiaquine (As + AQ), artesunate plus mefloquine (As + MQ) or dihydroartemisinin-piperaquine (DHAP). Laboratory technicians were masked to treatment allocation, but participants, clinicians, and study nurses were not. The primary outcomes were the cure rate and frequency of adverse events, which were assessed 6 weeks after treatment in the available case population using a per-protocol analysis. The non-inferiority margin was set at −10% for the risk difference in cure rates between combination therapy and PZQ alone. Between 12 September 2018 and 11 January 2019, 540 participants were assigned to receive PZQ alone ( n = 108), PZQ plus As + SP ( n = 108), PZQ plus As + AQ ( n = 108), PZQ plus As + MQ ( n = 108), or PZQ plus DHAP ( n = 108). Primary outcome data were available for 523 (96.9%) participants. The cure rate was 82.5% (85/103) in PZQ alone, 81.7% (85/104) in PZQ plus As + SP, 76.2% (80/105) in PZQ plus As + AQ, 88.7% (94/106) in PZQ plus As + MQ, and 85.7% (90/105) in PZQ plus DHAP arm. Non-inferiority was declared for PZQ plus As + MQ (difference 6.2 [95% confidence interval: −3.3 to 15.6]) and PZQ plus DHAP (3.2 [−6.7 to 13.1]) but not for PZQ plus As + SP (−0.8 [−11.2 to 9.6]) or PZQ plus As + AQ (−6.3 [−17.3 to 4.6]). Adverse events were reported by 26% (138/540) of participants, including abdominal pain, headache, and vomiting. There were no serious adverse events. Alternatives to praziquantel should include praziquantel plus artesunate-mefloquine or praziquantel plus dihydroartemisinin-piperaquine. However, further multicentre trials are needed in different epidemiological settings and population groups to confirm these findings. CLINICAL TRIALS This study is registered with the Pan-African Clinical Trials Registry under PACTR202001919442161 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
ORCID-Profile: Charles O Obonyo
Förderung
- Kenya Medical Research Institute (KEMRI)
Zitieren
APA
Obonyo, C. O., Were, V. O., Wamae, P., & Muok, E. M. O. (2025). Efficacy and safety of praziquantel plus artemisinin-based combinations versus praziquantel in the treatment of Kenyan children with Schistosoma mansoni infection: open-label, randomized, head-to-head, non-inferiority trial. Antimicrobial Agents and Chemotherapy, 69(2). https://doi.org/10.1128/aac.00739-24
Vancouver
Obonyo CO, Were VO, Wamae P, Muok EMO. Efficacy and safety of praziquantel plus artemisinin-based combinations versus praziquantel in the treatment of Kenyan children with Schistosoma mansoni infection: open-label, randomized, head-to-head, non-inferiority trial. Antimicrobial Agents and Chemotherapy. 2025;69(2). doi:10.1128/aac.00739-24
BibTeX
@article{Obonyo2025,
author = {Obonyo, Charles O and Were, Vincent O and Wamae, Peter and Muok, Erick M O},
title = {Efficacy and safety of praziquantel plus artemisinin-based combinations versus praziquantel in the treatment of Kenyan children with Schistosoma mansoni infection: open-label, randomized, head-to-head, non-inferiority trial},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {2},
doi = {10.1128/aac.00739-24}
}
EUVIMED